Top in allergy/asthma: Updates on omalizumab from the AAAAI Annual Meeting
Click Here to Manage Email Alerts
Robert Wood, MD, FAAAAI, professor of pediatrics Johns Hopkins University School of Medicine, recounted the results of the OUtMATCH study.
The results indicated that omalizumab (Xolair, Genentech/Novartis) was effective in protecting against type I reactions resulting from accidental ingestion among patients aged as young as 1 year with multiple -mediated food allergies.
It was the top story in allergy/asthma last week.
In another top story, Healio spoke with Wood to find out more about the results of the OUtMATCH study.
“If you compare peanut, to which all participants had to be allergic, 67% got a high level of protection, and 33% did not,” Wood said. “On the other hand, many of those 33% were protected compared with where they started at baseline.”
“We think it’s going to be a real game changer for a lot of patients,” he added.
Read these and more top stories in allergy/asthma below:
VIDEO: Omalizumab gives families with food allergy ‘some hope’ for normal lives
Robert Wood, MD, FAAAAI, recounted the results of the OUtMATCH study to a standing-room-only crowd at the American Academy of Allergy, Asthma & Immunology Annual Meeting. Watch here.
Q&A: Omalizumab provides protective effect for multiple food allergies
Patients with multiple food allergies experienced a protective effect against allergic reactions with omalizumab, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting. Read more.
On having empathy, understanding you belong in the room as a woman allergist
Payel Gupta, MD, FACAAI, says the busier she is, the more efficient she is, which may explain how she is able to balance caring for patients, running a company, hosting a podcast and teaching. Read more.
Healio introduces Women in Allergy, esteemed Peer Perspective Board
Healio has launched Women in Allergy, an initiative that aims to advance the work of women in allergy by providing insights for overcoming challenges and assistance in achieving better health care. Read more.
Omalizumab increases thresholds for reactions in multiple food allergies
Omalizumab increased thresholds for reacting to peanut and other common allergenic foods during accidental exposure, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting. Read more.